- American City Business Journals•13 days ago
The most Navidea Biopharmaceuticals Inc. could recover from the last of its legal battle with former lender CRG is $12 million – and the most it could lose is $7 million – after being forced to choose between pursuing a legal counterclaim or going out of business. Navidea's sale of North American rights to Lymphoseek, its first approved drug, to Cardinal Health Inc. for $83 million cash this month could not close until CRG released liens it placed on all of Navidea's assets. The lender, which had been pursuing a default claim and trying to seize Navidea's bank accounts since last April, released the liens only after Navidea agreed to a settlement requiring a promise not to pursue future claims against CRG.
- American City Business Journals•21 days ago
Navidea Biopharmaceuticals Inc. on Friday closed the sale of North American rights to its first approved drug to Cardinal Health Inc. for $83 million cash – 70 percent of which goes to fend off a lender trying for the past year to seize its bank accounts. The sale of the cancer diagnostic aid Lymphoseek could become worth $310 million over the life of the agreement , but most of the up-front payment is pledged elsewhere. From the proceeds, Navidea (NAVB) paid a $59 million temporary settlement with Houston-based lender CRG.
- Business Wire•23 days ago
Navidea Biopharmaceuticals announced today the completion of the sale to Cardinal Health of its Lymphoseek® product for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America.
NAVB : Summary for Navidea Biopharmaceuticals, Inc - Yahoo Finance
Navidea Biopharmaceuticals, Inc (NAVB)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.56 - 0.58|
|52 Week Range||0.26 - 1.51|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.99|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|